re.Mind Capital

Great to see 4 @reMindCapital portfolio companies feature in @mcjomcg's inside look into the world of brain-computer interfaces. We are big believers in #neurotech and proud to support @motifneuro, @PrecisionNeuro7, @synchroninc, @BlackrockNeuro_. wsj.com/science/inside…

📅 One week to go before @TechTourHQ Mental & Brain Health event! EBC’s Deputy Executive Director Stephanie Kramer is pleased to join the panel discussion “Is – or how can we make – mental health and brain health a government policy priority?”. 🔍 braincouncil.eu/event/tech-tou…

Check out this @Reuters story about @reMindCapital portfolio company, @synchroninc - one of the true leaders in brain-computer interfaces and #neurotech.

We recently initiated a Phase 2 study of ALTO-203 in people with MDD & higher levels of #anhedonia. We look forward to continuing to study the potential of #PrecisionPsychiatry. Check out this @PsychTimes article to learn more: brnw.ch/21wIEKC

We're looking for a Research Sales Specialist to hire. If you've got a passion for technology and want to collaborate with top research institutions on groundbreaking neuroscience, we want to hear from you. Apply here: ats.rippling.com/blackrockneuro…

For insight into how a pre-revenue #BCI company approaches reimbursement strategy at this stage, our Chief Commercial Officer @KurtHaggstrom speaks with @forbes columnist @naveen101 forbes.com/sites/naveenra…

Our team: data scientists 🤝 clinical experts. We put data at the forefront of our work to inform our #PrecisionPsychiatry approach. Learn how we are working to eliminate trial-and-error from #MentalHealth drug development: brnw.ch/21wHbsn

At Alto, everything we do is rooted in our core values. We aim to defeat the global #MentalHealth crisis one brain at a time. For us, it's about the differences we make in the lives of every person we impact. Learn more about our values and mission here: brnw.ch/21wH0pr

All things leadership 🎙️ We’re curious about the advice of some of the greatest leaders in healthcare. Tune into this episode of The Cure(ious) #cureious-about-leadership" target="_blank" rel="nofollow noopener">nyse.com/insights/the-c…

We are thrilled to welcome Dr. Husseini Manji to Alto’s Board of Directors. Bringing decades of experience spanning both industry and academia, Dr. Manji embodies Alto’s value “Invested in Impact” through his commitment to redefining #psychiatric treatment for patients.

Congratulations @AltoNeuro !!! #mentalhealth

A huge congratulations to @AmitEtkin and the entire @AltoNeuro team for reaching this IPO milestone. We're proud investors and supporters of their vision, and we can't wait to see what the next chapter holds in store. 🧠 #NextHumanAgenda #Biotech #AI

Our product candidates in development target core #brain processes, including: 🧠 Cognition 🙂 Emotion and its regulation 💤 Sleep and circadian rhythms Learn more: brnw.ch/21wGjyK

We are one of the top 50 places to work! 🙌 We're delighted to have been named one of @BuiltIn's top 50 places to work – both in-person and remotely. This speaks to our dedication to creating a global workplace that inspires innovation, champions our team, and supports the whole atai team – wherever they are based. A big thank you to everyone in the @atai_life team - your passion, creativity, and collaborative spirit make this a fantastic place to be. builtin.com/awards/best-sm… #BPTW2024 #2024BuiltInBest

re.Mind Capital is proud to have been part of @motifneuro's Series A raise. Congrats to @JTRobinsonLab and his team! The work they're doing to develop an implantable device for treatment-resistant depression will help transform the future of #mentalhealth #neurotech

#DYK that our clinical-stage pipeline includes novel drug candidates in #Depression, #PTSD, #Schizophrenia, and other #MentalHealth conditions? Learn more about our pipeline and target indications: brnw.ch/21wG7uo

Don't miss our founder, @C_Angermayer, in conversation with @TheDalesReport about the thawing of the biotech winter and @atai_life's strategic investment in @BeckleyPsytech. #NextHumanAgenda #Psychedelics #Biotech thedalesreport.com/psychedelics/h…

Happy New Year from everyone at @ApeironInvests. Here’s to a wonderful 2024 for all! 🎉🍾🥳🎇

#Psychiatry is an ever-changing field, and treatment options will continue to evolve in 2024. At Alto, we are passionate about developments in the #MentalHealth treatment landscape and furthering our mission to bring personalized, effective treatments to people in need.

Happy holidays from the Alto Team! We're planning to spend this holiday season prioritizing our mental health and spending some time with family and loved ones.